Lorcaserin Hcl for the treatment of obesity

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 16, 2015, Pages 2531-2538

  Shukla, Alpana P ^a   Kumar, Rekha B ^a   Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

5HT2C agonist; behavioral modification and lorcaserin for overweight and obesity management; behavioral modification and lorcaserin second study for obesity management; lorcaserin; obesity

Indexed keywords

LORCASERIN; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; SEROTONIN 2 AGONIST;

ARTICLE; BODY WEIGHT; BODY WEIGHT MANAGEMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; MARKET; METABOLIC PARAMETERS; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WEIGHT REDUCTION; ANIMAL;

ANIMALS; ANTI-OBESITY AGENTS; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; HUMANS; OBESITY; SEROTONIN 5-HT2 RECEPTOR AGONISTS;

EID: 84947489689     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1096345     Document Type: Article

References (36)

1. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among us adults, 1999-2010. JAMA 2012;307(5):291-497
2. Korner J, Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest 2003;111(5):565-70
3. Lowe M. Self-regulation of energy intake in the prevention and treatment of obesity: is it feasible? Obes Res 2003;11(Suppl):44S-59S
4. National Institutes of Health, National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults 2002. NIH publication number 02-4084
5. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352(9123):167-72
6. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9774):1341-52
7. Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21(5):935-43
8. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373(1):11-22
9. Burke LK and Heisler LK. 5-Hydroxytryptamine Medications for the Treatment of Obesity. J Neuroendocrinol 2015;27:389-98
10. Saller CF, Stricker EM. Hyperphagia and increased growth in rats after intraventricular injection of 5,7-dihydroxytryptamine. Science 1976;192:385-7
11. Breisch ST, Zemlan FP, Hoebel BG. Hyperphagia and obesity following serotonin depletion by intraventricular p-chlorophenylalanine. Science 1976;192:382-5
12. Jackson HC, Needham AM, Hutchins LJ, et al. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997;121:1758-62
13. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995;374:542-6
14. Lopez-Gimenez JF, Mengod G, Palacios JM, et al. Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with as demonstrted by [3H] mesulergine binding sites and choline acetyltransferase mRNA. Synapse 2001;42:12-26
15. Pasqualetti M, Ori M, Castagna M, et al. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 1999;92:601-11
16. Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab 2007;6:398-405
17. Nonogaki K, Strack AM, Dallman MF, et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998;4:1152-6
18. Xu Y, Berglund ED, Sohn JW, et al. 5-HT2CRs expressed by proopiomelanocortin neurons regulate insulin sensitivity in liver. Nat Neurosci 2010;13:1457-9
19. Berglund ED, Liu C, Sohn JW, et al. Serotonin 2C receptors in proopiomelanocortin neurons regulate energy and glucose homeostasis. J Clin Invest 2013;123:5061-70
20. Hoy SM. Lorcaserin: A review of its use in chronic weight management. Drugs 2013;73(5):463-73
21. Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab 2011;96(3):837-45
22. Burke LK, Doslikova B, D'Agostino G, et al. 5-HT obesity medication efficacy via POMC activation is maintained during aging. Endocrinology 2014;155:3732-8
23. BELVIQ (lorcaserin hydrochloride) [package insert]. Zofingen, Switzerland: Arena Pharamceuticals. 2014
24. Aronne LJ, Powell AG, Apovian CM. Emerging pharmacotherapy for obesity. Expert Opin Emerg Drugs 2011;16(3):587-96
25. Connolly HM, Crary JL, McGoon MD, et al. Valvular Heart Disease Associated with Fenfluramine-Phentermine. NEJM 1997;337(9):581-8
26. Arena Pharmaceuticals announces results of its phase lb safety study for its novel anti-obesity compound. Arena Pharmaceuticals 2004 Nov 3; [news release]
27. Smith SR, Prosser WA, Donahue DJ, et al. APD356-004 Study Group. Lorcaserin (APD356) a selective 5-HT (2C) agonist reduces body weight in obese men and women. Obesity (Silver Spring) 2009;17(3):494-503
28. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56
29. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab 2011;96(10):3067-77
30. O'Neil P, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of. Lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity 2012;20(7):1426-36
31. Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: A combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med 2014;126(6):7-18
32. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6(4):560-7
33. Available from: www.clinicaltrials.gov [Last accessed 12 July 2015]
34. Smith SR, O'Neil PM, Astrup A, et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring) 2014;22(10):2137-46
35. Smith, SR, et al. Combination weight management with loracaserin and phentermine. TOS2015 Abstract-TLB-2053-P
36. Apovian CM, Aronne L, Powell AG. Clinical Management of Obesity 220-221 Professional Communications,Inc 2015